Development of precision medicine applications for frailty prediction and healthy aging.

The bG23 project builds on the achievements of Elkartek bG19 and bG21, which developed integrated omics analysis platforms (metabolomics, proteomics, fluxomics, microbiotics, and genomics). Leveraging this progress, the consortium aims to apply precision medicine to the study of frailty and healthy aging. The main goal is to identify a metabolic fingerprint that, through an algorithm, can quantify a person’s frailty index at different ages and analyze its link to medical complications.
Frailty is defined as a decline in physiological capacity that increases vulnerability to external stressors, affecting not only physical but also psychological and social well-being. Early detection is crucial to prevent falls, disabilities, and hospitalizations. Two main approaches are used to assess frailty: the phenotypic definition, which views it as a syndrome, and the cumulative deficit model, which sees it as a continuum of aging. However, no universal standard measure exists.
The bG23 project aims to fill this gap by using metabolomic data and advanced analytical tools to develop predictive models that support personalized prevention and treatment strategies, promoting more precise healthcare and healthy aging.